Roche Wins Approval for Targeted Cancer Drug Vismodegib
Date Posted: January 31, 2012
Date Posted: January 31st, 2012 Summary: Yesterday the FDA announced that Roche and Genentech had been granted approval for the targeted cancer drug, Vismodegib for the treatment of basal cell carcinoma. The approval was granted under the agency’s priority review program that provides for an expedited six-month review of drugs that may offer major advancesContinue Reading

The Team